Clinical utility of circulating tumor cell count as a tool to chose between first line hormone therapy and chemotherapy for ER+HER2-metastatic breast cancer: Results of the phase III STIC CTC trial-MedSci.cn

Clinical utility of circulating tumor cell count as a tool to chose between first line hormone therapy and chemotherapy for ER+HER2-metastatic breast cancer: Results of the phase III STIC CTC trial

Bidard, FC; Jacot, W; Dureau, S; Brain, E; Bachelot, T; Bourgeois, H; Goncalves, A; Ladoire, S; Naman, H; Dalenc, F; Gligorov, J; Espie, M; Levy, C; Ferrero, JM; Loirat, D; Cottu, P; Dieras, V; Simondi, C; Berger, F; Alix-Panabieres, C; Pierga, JY

CANCER RESEARCH, 2019; 79 (4):

科室
- - 订阅+
  - 更多科室
工具
服务